STOCK TITAN

Immunome Inc - IMNM STOCK NEWS

Welcome to our dedicated news page for Immunome (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunome's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunome's position in the market.

Rhea-AI Summary
Immunome, Inc. completes merger with Morphimmune, appoints Clay B. Siegall as Chairman and CEO. $125 million private placement investment secured. Expected to submit three INDs within 18 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.24%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
Immunome Inc

Nasdaq:IMNM

IMNM Rankings

IMNM Stock Data

1.23B
44.03M
18.1%
37.51%
5.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Bothell

About IMNM

immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. this proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. we then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.